Decreased nonvertebral fracture incidence with zoledronate use for >3 years: post hoc analysis of a Randomized Controlled Trial
Ian R Reid, Anne M Horne, Borislav Mihov, Sonja Bastin, Mark J Bolland, Gregory D Gamble · 2026
Read Decreased nonvertebral fracture incidence with zoledronate use for >3 years: post hoc analysis of a Randomized Controlled Trial by Ian R Reid, Anne M Horne, Borislav Mihov, Sonja Bastin, Mark J Bolland, Gregory D Gamble (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13525198.txt.
Description
Reid and colleagues ask whether a bone drug works better the longer it is taken. Their 2026 post hoc analysis revisits a six-year Auckland trial in which 2,000 osteopenic women over 65 received zoledronate or placebo every eighteen months. Most trials stop at three years and lose their placebo group, but this one kept both, letting the authors compare fracture protection between the trial's two halves.
In the placebo group, non-vertebral fracture rates stayed roughly flat across both halves. In the zoledronate group, the rate fell from 23 to 13 fractures per thousand women-years between the first and second halves. The relative protection strengthened accordingly, from a rate ratio of 0.83 in years one to three to 0.40 in years four to six, a significant difference between periods. The authors suggest long-term fracture prevention by such drugs has been underestimated.
Catalog record
| CREATOR | Ian R Reid, Anne M Horne, Borislav Mihov, Sonja Bastin, Mark J Bolland, Gregory D Gamble |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 19 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |